Redcare Pharmacy, NL0012044747

Redcare Pharmacy stock last at EUR 61.10, up 2.78 percent in Xetra trading

Published on 09/25/2026 at 20:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Redcare Pharmacy stock traded between EUR 59.45 and EUR 61.75 on September 25, 2026, before standing at EUR 61.10 in Xetra trading. The shares outperformed the SDAX, which gained 0.6 percent.

Automatisiertes Apotheken-Lager mit Robotersystem und unbeschrifteten Medikamentenboxen
Redcare Pharmacy (Shop Apoth), ISIN NL0012044747, zeigt automatisiertes Apotheken-Lager mit Roboter-Regalsystem und markenfreien Medikamentenschachteln, Illustration mit AI erstellt.

Redcare Pharmacy stock was last at EUR 61.10 on Xetra at 5:29 p.m. CET on September 25, 2026, up 2.78 percent or EUR 1.65 from the previous session. The shares outperformed the SDAX, which gained 0.6 percent during the session. European equities also benefited from softer oil prices, according to Reuters.

The session on September 25, 2026 in figures

Redcare Pharmacy N.V. (ISIN NL0012044747) traded between EUR 59.45 and EUR 61.75 in Xetra data for September 25. The EUR 61.75 intraday high was also the level cited in the Friday market report, while the EUR 59.45 low matched the previous session's reported Xetra level. The shares stood EUR 1.65 above the previous session's EUR 59.45 reference at 5:29 p.m. CET.

Redcare Pharmacy shares continued the advance that followed Thursday's move, with the price at EUR 61.75 around midday before easing to EUR 61.10 in the late Xetra phase. The displayed gain of 2.78 percent exceeded the SDAX's 0.6 percent rise by 2.18 percentage points. The September 25 quote represented a recovery from the recent monthly weakness described in the market report.

Deutsche Bank support and market factors on September 25, 2026

Deutsche Bank Research maintained its Buy rating for Redcare Pharmacy on September 25. Analyst Jan Koch described the recent share weakness as an attractive entry opportunity and recommended the bank's Buy Idea, as Deutsche Bank Research stated.

Koch said third-quarter results should support the recently raised annual targets. He also pointed to increasingly strong expected earnings growth in 2027 and anticipated no regulatory headwinds. The analyst view provided a company-specific support factor alongside the broader European market recovery.

SDAX and European market factors on September 25, 2026

The SDAX gained 0.6 percent on September 25 as Redcare Pharmacy ranked among its stronger performers. The STOXX 600 finished 0.4 percent higher, extending its weekly advance to 0.5 percent, according to Reuters. Banks led European sector gains with a 1.3 percent rise, while financial services advanced 1.1 percent. Softer oil prices supported equities, while elevated bond yields, cautious central bank signals and Middle East tensions limited the broader advance.

Disclaimer...

en | NL0012044747 | REDCARE PHARMACY | boerse | 70185236 | bgmi